Background-Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic heart failure. Activation of presynaptic ␣ 2 -adrenoceptors is the most widely accepted mechanism of action of the antisympathetic drug clonidine; however, other target proteins have been postulated to contribute to the in vivo actions of clonidine. Methods and Results-To test whether clonidine elicits pharmacological effects independent of ␣ 2 -adrenoceptors, we have generated mice with a targeted deletion of all 3 ␣ 2 -adrenoceptor subtypes (␣ 2ABC Ϫ/Ϫ ). ␣ 2ABC Ϫ/Ϫ mice were completely unresponsive to the analgesic and hypnotic effects of clonidine; however, clonidine significantly lowered heart rate in ␣ 2ABC Ϫ/Ϫ mice by up to 150 bpm. Clonidine-induced bradycardia in conscious ␣ 2ABC Ϫ/Ϫ mice was 32.3% (10 g/kg) and 26.6% (100 g/kg) of the effect in wild-type mice. A similar bradycardic effect of clonidine was observed in isolated spontaneously beating right atria from ␣ 2ABC -knockout and wild-type mice. Clonidine inhibited the native pacemaker current (I f ) in isolated sinoatrial node pacemaker cells and the I f -generating hyperpolarization-activated cyclic nucleotide-gated (HCN) 2 and HCN4 channels in transfected HEK293 cells. As a consequence of blocking I f , clonidine reduced the slope of the diastolic depolarization and the frequency of pacemaker potentials in sinoatrial node cells from wild-type and ␣ 2ABC -knockout mice. Conclusions-Direct inhibition of cardiac HCN pacemaker channels contributes to the bradycardic effects of clonidine gene-targeted mice in vivo, and thus, clonidine-like drugs represent novel structures for future HCN channel inhibitors.
S ympathetic control of heart rate plays an important role in the pathophysiology of arrhythmias, hypertension, coronary heart disease, and chronic heart failure. At present, 3 pharmacological strategies are used in clinical medicine to reduce increased sympathetic tone, including ␣ 2 -agonists, ␤-adrenoceptor antagonists, and, most recently, hyperpolarization-activated cyclic nucleotide-gated (HCN) pacemaker channel inhibitors. 1, 2 The first antisympathetic drug established in clinical therapy was clonidine (for reviews, see Schmitt 3 and Hoefke and Kobinger 4 ). Investigation into the mechanism of action of clonidine led to the identification of ␣ 2 -adrenoceptors as the main target of the action of clonidine. 5 Despite the fact that clonidine has vasoconstrictive properties, it was introduced into clinical practice as an antihypertensive and antisympathetic drug. Clonidine may act at 2 anatomic sites to lower blood pressure. 6 In several brain stem nuclei, activation of ␣ 2 -adrenoceptors leads to a reduction in sympathetic tone. In addition, clonidine may activate presynaptic inhibitory ␣ 2 -adrenoceptors on postganglionic sympathetic fibers to lower sympathetic norepinephrine release.
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Later, pharmacological ligands were applied to identify subtypes of ␣ 2 -receptors, which were confirmed by molecular cloning of 3 independent ␣ 2 -adrenoceptor genes from different species (␣ 2A , ␣ 2B , and ␣ 2C ). 7 The physiological significance of the 3 ␣ 2 -adrenoceptor subtypes was then highlighted by targeted deletions in the murine genes. 8 With these gene-targeted mouse models, the 2 major actions of clonidine and other ␣ 2 -agonists, hypotension and sedation, could be assigned to activation of ␣ 2A -receptors, whereas ␣ 2B -receptors were involved in vasoconstriction, and ␣ 2C took part in modulation of catecholamine release. 9 -11 However, several reports had suggested that not all of the effects of clonidine were dependent on ␣ 2 -adrenoceptors, which led to the development of the "imidazoline receptor hypothesis." 12 Several different imidazoline binding sites were proposed (for review, see Szabo 6 ); however, the molecular identity of the putative I 1 imidazoline receptor that was suggested to be responsible for the hypotensive effect of clonidine and other imidazolines has not yet been uncovered.
To search for non-␣ 2 -adrenoceptor effects of clonidine, we have generated mice lacking all 3 ␣ 2 -adrenoceptors (␣ 2ABC
Ϫ/Ϫ
). This led to the identification of a direct bradycardic effect of clonidine by inhibition of the cardiac hyperpolarization-activated ("pacemaker") current (I f ). I f has been shown to play a key role in the generation of pacemaker potentials in sinoatrial node (SAN) cells of the heart. 1,2,13 Moreover, I f is enhanced by direct interaction with cyclic adenosine monophosphate and, hence, contributes to the autonomous regulation of heart rate by the sympathetic and parasympathetic nervous system. I f is encoded by a family of 4 HCN channels (HCN1-4). 14 In mouse SAN, HCN4 and HCN2 are the predominantly expressed HCN channel isoforms. [15] [16] [17] The same isoforms have been also detected in human heart tissue. 18 Mouse SAN does not express substantial levels of HCN1, but higher levels of this subunit (Ϸ20% of total HCN mRNA) were found in rabbit SAN. 15 Here, we show that clonidine blocks both HCN2 and HCN4 channels in the low micromolar concentration range and, as a consequence, lowers the frequency of pacemaker potentials.
Methods

Generation of ␣ 2ABC
؊/؊ Mice
The generation of ␣ 2ABC Ϫ/Ϫ has been described previously. 19 From the initial intercrossing of Adra2a Ϫ/Ϫ Adra2b ϩ/Ϫ Adra2c Ϫ/Ϫ mice, a small percentage survived a defect in placental development. These mice were used to establish an independent colony of ␣ 2ABC -deficient mice. Mice were maintained in a specified pathogen-free facility. All animal procedures were approved by the Universities of Freiburg and Würzburg.
Autoradiography and Radioligand Binding
Mouse brain membranes 20 [ 3 H]norepinephrine release was determined in cardiac atria essentially as described previously with minor modifications. 11, 20 [ 3 H]norepinephrine release was evoked by short trains of rectangular electrical pulses (4 pulses, 100 Hz). The amount of radioactivity released from the tissues was determined by liquid scintillation counting. 11
Norepinephrine Release
Twenty-Four-Hour Urinary Catecholamine Determination
Catecholamine excretion was quantified by high-performance liquid chromatography combined with electrochemical detection of urine samples collected over 24-hour periods in metabolic cages as described previously. 21 
Sedation and Analgesia
Fifteen minutes after clonidine injection (1 mg/kg IP), mice were placed 3 times on a rotating wheel (rotating speed 10 rpm); maximal cutoff time was 60 seconds. For analgesia testing, a tail-flick assay system (Ugo Basile, Comerio, Italy), equipped with an infrared light source and automatic recording of the reaction time, was used.
Hemodynamic Measurements
For cardiac, aortic, or femoral artery catheterization with a 1.4F Millar microtip device, mice were anesthetized by isoflurane (2 vol% in O 2 ) applied by face mask and kept on a heating table at 37°C. 22 Hemodynamic parameters were digitized via a MacLab system (AD Instruments, Castle Hill, Australia). Transthoracic echocardiography Doppler examinations were performed in lightly sedated (200 L 2.5% tribromoethanol IP) mice with an echocardiographic system (Acuson Sequoia C512, Siemens AG, Erlangen, Germany) equipped with a 15-MHz linear transducer (Acuson, 15L8). For measurements in conscious, unrestrained mice, blood pressure and ECGs were recorded by telemetry (DSI, Transoma Medical, St. Paul, Minn; PA10 for aortic pressure, TC10 for ECG) 10 to 20 days after surgery.
Histology
Hearts were fixed with 4% paraformaldehyde in phosphate-buffered saline (pH 7.4), embedded in paraffin, and stained with hematoxylineosin. Left ventricular myocyte cross-sectional areas were analyzed by computer-assisted morphometry. To detect interstitial fibrosis, hearts were stained with Sirius red as described previously. 22 
Organ Bath Experiments
Hearts were rapidly excised and placed in carbogenated modified Tyrode's solution (concentrations in mmol/L: 119 NaCl, 5.4 KCl, 1.4 CaCl 2 , 1 MgCl 2 , 22.6 NaHCO 3 , 0,42 NaH 2 PO 4 , 0.025 EDTA, 10 glucose, 0.2 ascorbic acid, pH 7.4). Right atria of 3-to 4-month-old mice were mounted in an organ bath chamber and were allowed to contract spontaneously. ␣ 2ABC -Knockout (KO) mice were injected 16 hour antemortem with pertussis toxin 150 g/kg IP (Sigma, Munich, Germany). 23 
Cell Culture and Isolation of Murine SAN Cells
Human embryonic kidney (HEK)-293 cell lines stably expressing either murine HCN2 or human HCN4 were maintained as described previously. 18, 24 SAN cells were isolated from 6-to 12-week-old adult ␣ 2ABC ϩ/ϩ and ␣ 2ABC Ϫ/Ϫ mice of either sex by standard procedures. 25, 26 
Electrophysiological Recordings
Native I f and heterologously expressed HCN channels were measured at room temperature with the whole-cell voltage-clamp technique as described previously. 25 The extracellular solution was composed of (in mmol/L): 135 NaCl, Effects of clonidine were determined with a repetitive stimulation protocol. Hyperpolarizing pulses of 1.0-second duration (for HCN2, HCN1, and native I f ; test potential Ϫ100 mV for HCN2 and native I f and Ϫ90 mV for HCN1) or 1.5-second duration (for HCN4, test potential Ϫ110 mV) were applied from a holding potential of Ϫ40 mV every 2 seconds (HCN2, HCN1, and native I f ) or every 3 seconds (HCN4), and the resulting inward currents were determined. The longer pulse duration for HCN4 was chosen with respect to the slow activation kinetics of this channel. For determination of dose-response relationships, the maximum inward current corrected for the instantaneous current component of I f 27 was obtained after repetitive stimulation for 1 minute. IC 50 values and Hill coefficients () were calculated by fitting with the Hill equation. Steady-state activation curves were determined by hyperpolarizing voltages of Ϫ140 to Ϫ30 mV from a holding potential of Ϫ40 mV for 2.4 seconds followed by a step to Ϫ140 mV. Tail currents, measured immediately after the final step to Ϫ140 mV, were normalized by the maximal current (I max ) and plotted as a function of the preceding membrane potential. The data points were fitted with the Boltzmann function: (I-I min )/ (I max ϪI min )ϭ{1Ϫexp[(V m ϪV 0.5 )/k]} where I min is an offset caused by a nonzero holding current, V m is the test potential, V 0.5 is the membrane potential for half-maximal activation, and k is the slope factor.
Statistical Analysis
Data were analyzed by ANOVA followed by appropriate post hoc tests, by Student t test for unpaired samples, by paired-samples t test, or by repeated-measures test when appropriate. A probability value of Ͻ0.05 was considered statistically significant. Results are displayed as meanϮSEM.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Generation of Mice Deficient in ␣ 2ABC -Adrenoceptors
Mice lacking all 3 ␣ 2 -adrenoceptor subtypes (␣ 2ABC Ϫ/Ϫ ) were derived from matings of male and female Adra2a 19 Initially, a high percentage of ␣ 2ABC Ϫ/Ϫ mice died during embryonic development due to a defect in placental vascular development 19 ; however, from surviving ␣ 2ABC Ϫ/Ϫ mice, a breeding colony could be established ( Figure 1 ). Several methods were applied to document the deletion of all 3 ␣ 2 -adrenoceptor genes. Autoradiography with the ␣ 2 -receptor antagonist [ 3 H]RX821002 revealed a high density of ␣ 2 -receptor binding sites in wild-type brain. In the presence of the specific ␣ 2 -adrenoceptor antagonist atipamezole, this signal was absent in ␣ 2ABC ϩ/ϩ brains and was also undetectable in brain sections of ␣ 2ABC Ϫ/Ϫ mice ( Figure 1b) . Similarly, quantitative radioligand binding did not detect any specific ␣ 2 -adrenoceptors in brain membranes of ␣ 2ABC Ϫ/Ϫ mice ( Figure 1c) .
To further verify the complete deletion of the 3 ␣ 2 -adrenoceptor genes, pharmacological tests for typical ␣ 2 -receptor functions were performed. Intraperitoneal injection of the ␣ 2 -agonist clonidine resulted in a shortened latency time on a rotating wheel, which demonstrates its sedating effect in ␣ 2ABC ϩ/ϩ mice (Figure 2a ). In contrast, clonidine did not induce sedation in ␣ 2ABC Ϫ/Ϫ mice (Figure 2a) . Similarly, the analgesic properties of clonidine could be verified by an increased latency time in the tail-flick assay in wild-type mice but not in ␣ 2ABC Ϫ/Ϫ mice (Figure 2b ). Another important function of ␣ 2 -adrenoceptors is their role in presynaptic feedback inhibition of neurotransmitter release. In isolated heart atria from wild-type mice, norepinephrine (Figure 2c ) and the ␣ 2 -agonist medetomidine (not shown) inhibited the electrically evoked release of [ 3 H]norepinephrine in a concentration-dependent manner. In ␣ 2ABC Ϫ/Ϫ atria, norepinephrine did not inhibit sympathetic transmitter release. Genetic disruption of presynaptic feedback inhibition also resulted in enhanced sympathetic neurotransmitter release in vivo, as evidenced by increased norepinephrine excretion in 24-hour urine samples of ␣ 2ABC
Ϫ/Ϫ compared with wild-type mice (Figure 2d ).
Cardiovascular Function in ␣ 2ABC -Deficient Mice
To determine the long-term consequences of enhanced sympathetic tone, we first assessed cardiovascular function in conscious, freely-moving ␣ 2ABC Ϫ/Ϫ mice by telemetry (Figures  3a through 3c) . Enhanced sympathetic norepinephrine release in ␣ 2ABC Ϫ/Ϫ mice was accompanied by increased systolic and diastolic blood pressures and elevated heart rate (Figures 3a  through 3c ). At the age of 6 months, however, cardiac function was already compromised. Left ventricular fractional shortening was reduced to 33% in ␣ 2ABC Ϫ/Ϫ animals compared with 50% in wild-type mice (Figure 3d ). In addition, severe cardiac fibrosis and hypertrophy were detected in left ventricles of ␣ 2ABC Ϫ/Ϫ hearts (Figures 3e  through 3g) .
Next, we assessed the effects of the ␣ 2 -agonist clonidine on blood pressure and heart rate. In wild-type mice, clonidine significantly reduced mean arterial pressure and heart rate during isoflurane anesthesia (Figure 4a) . Surprisingly, the bradycardic effect of clonidine was still present in ␣ 2ABC Ϫ/Ϫ mice (Figure 4a) , whereas its hypotensive effect was com- pletely absent in these animals. To determine heart rate in awake mice without disrupting the baroreflex, telemetric ECG transducers were implanted subcutaneously. In awake wild-type mice, clonidine lowered resting heart rate dosedependently by up to 250 bpm (300 g/kg IP; Figure 4b ). Clonidine also lowered heart rate in ␣ 2ABC -deficient mice. Its effect in ␣ 2ABC Ϫ/Ϫ mice reached 32.3%, 26.6%, and 42.6% of the bradycardia observed in wild-type mice at 10, 100, and 300 g/kg IP, respectively (Figure 4b) .
To identify the site of the bradycardic action of clonidine, isolated spontaneously beating right atria were tested in an organ bath system. Clonidine reduced beating frequency by 20% to 25% in atria from both genotypes (Figure 5a ). Clonidine concentrations reducing the right atrial frequency by 50% did not differ between genotypes (␣ 2ABC ϩ/ϩ 4.9 mol/L versus ␣ 2ABC Ϫ/Ϫ 4.4 mol/L). The concentrations required to lower spontaneous beating rate by 20% did not differ between clonidine and the HCN inhibitor ZD7288 (Figure 5a, inset) . After pertussis toxin pretreatment of mice to inactivate G proteins of the G i/o family, the bradycardic effect of the muscarinic agonist carbachol was completely eliminated (Figure 5b ). Pertussis toxin did not affect the clonidine-induced bradycardia, which ruled out the possibility that G i/o -coupled receptors mediated the bradycardia. Similarly, incubation with 100 mol/L Ba 2ϩ , a blocker of inwardly rectifying K ϩ channels, did not alter the clonidine effect ( Figure 5c) ; however, in the presence of 2 mmol/L Cs ϩ , an established blocker of cardiac I f , the clonidine-induced bradycardia was completely absent (Figure 5c ).
Clonidine Is an Efficient Blocker of Sinoatrial I f
The strong Cs ϩ sensitivity of the bradycardic effect of clonidine suggested that clonidine may act via I f channels. To explore this hypothesis, we first characterized spontaneous action potentials of pacemaker cells isolated from the SAN of wild-type and ␣ 2ABC Ϫ/Ϫ mice (Figures 6a and 6b ). Clonidine were assessed in awake, unrestrained mice by pressure telemetry. Mean 24-hour systolic and diastolic blood pressure and heart rate were significantly higher in ␣ 2ABC Ϫ/Ϫ mice than in wildtype mice (nϭ6 mice per genotype). d, Cardiac contractile performance was determined by echocardiography under anesthesia with tribromoethanol. Left ventricular fractional shortening was reduced in ␣ 2ABC Ϫ/Ϫ mice compared with wild-type controls (*PϽ0.05; nϭ4 mice per genotype). e, Areas of interstitial fibrosis are visible in the left ventricular wall of ␣ 2ABC Ϫ/Ϫ but not in ␣ 2ABC ϩ/ϩ hearts by Sirius red staining (male mice, age 6 to 9 months). Barϭ50 m. f and g, Cardiac hypertrophy in ␣ 2ABC Ϫ/Ϫ can be detected as an increased heart weight/body weight ratio (f, ␣ 2ABC ϩ/ϩ nϭ32, ␣ 2ABC Ϫ/Ϫ nϭ66 mice), as well as increased cross-sectional area of cardiac myocytes (g, nϭ6 hearts per genotype, *PϽ0.05).
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profoundly lowered the frequency of pacemaker potentials in SAN cells from both genotypes. Clonidine increased the duration between 2 peaks (cycle length) from 455Ϯ48 to 1105Ϯ223 ms (nϭ6) in wild-type mice and from 605Ϯ45 to 895Ϯ98 ms (nϭ4) in ␣ 2ABC Ϫ/Ϫ mice (Figures 6a and 6b ). Although the increase in cycle length induced by clonidine was highly significant in both genotypes, the absolute values of cycle length in the absence and presence of clonidine, respectively, were not statistically different between genotypes. The frequency reduction of pacemaker potentials by clonidine was accompanied by a reduction of the slope of the diastolic depolarization (wild-type: from 79.7Ϯ8.1 to 45.6Ϯ6.6 mV/s, nϭ6, PϽ0.05; ␣ 2ABC Ϫ/Ϫ : from 62.1Ϯ9.9 to 34.1Ϯ7.9 mV/s, nϭ4, PϽ0.05). In contrast, other parameters of the pacemaker potential (maximum diastolic potential, overshoot, and action potential duration) were unaffected by clonidine (Data Supplement, Table I ). The reduction of the slope of diastolic depolarization could be caused by an inhibition of the I f current. Indeed, clonidine efficiently blocked this current in a dose-dependent manner (Figures 6c   and 6d) . The IC 50 values at Ϫ100 mV were 3.1Ϯ0.5 mol/L (nϭ5 to 11) and 2.8Ϯ0.7 mol/L (nϭ5 to 8) for wild-type and ␣ 2ABC Ϫ/Ϫ mice, respectively, which is in excellent agreement with the IC 50 values determined in beating right atria (Figure 5a ). I f had the same amplitude in wild-type and ␣ 2ABC Ϫ/Ϫ cells (Ϫ5.3Ϯ0.8 versus Ϫ6.1Ϯ1 pA/pF, nϭ13, Pϭ0.2). Moreover, kinetics and voltage-dependence of I f were indistinguishable between genotypes (data not shown). Cardiac I f is mediated by HCN4 and HCN2 channels; therefore, we tested the effect of clonidine on HEK293 cell lines that stably expressed either or both channels (Figures 7a  and 7b ). Clonidine inhibited both channels in a dosedependent manner. The IC 50 values were slightly higher than those of native I f (9.8Ϯ1.4 mol/L [nϭ7 to 12] for HCN4 and Ϫ/Ϫ mice reveal bradycardic effects of clonidine in both mouse strains without significant changes in blood pressure in ␣ 2ABC Ϫ/Ϫ mice. b, Bradycardic effect of clonidine in awake, freely moving mice with implantation of a telemetric ECG transducer. Clonidine lowered heart rate in conscious animals of both genotypes (nϭ6 to 9 mice per genotype, repeated-measures test, *PϽ0.05 drug vs untreated). n.d. indicates not determined. Figures 7c and 7d) . Interestingly, in the presence of 100 mol/L Cs ϩ , which corresponds to the half-maximal inhibitory concentration of this cation, the clonidine binding curve for HCN2 was shifted to the right (IC 50 ϭ16.3Ϯ1.4 mol/L; nϭ12). This finding suggested that Cs ϩ and clonidine may competitively bind to the same channel region. Clonidine not only blocked I f , it also shifted the voltage-dependence of channel activation by 10 to 20 mV to more hyperpolarizing potentials (Figures 8a  through 8d ). Clonidine also inhibited HCN1 currents, although with significantly lower sensitivity (IC 50 ϭ40.1Ϯ4.34 mol/L; nϭ7 to 9). By contrast, clonidine had virtually no effect on voltage-gated calcium and sodium channels (Data Supplement, Figure I ).
Discussion
The main finding of the present study is the identification of a direct inhibitory effect of the ␣ 2 -receptor agonist, clonidine, on cardiac pacemaker channels (HCN). To uncover this effect of clonidine, we have generated mice with targeted deletions in all 3 ␣ 2 -adrenoceptor genes.
To verify that no functional ␣ 2 -adrenoceptors remained in ␣ 2ABC
Ϫ/Ϫ mice, we performed a number of experiments. Radioligand binding experiments and autoradiography confirmed the absence of ␣ 2 -adrenoceptor protein in ␣ 2ABC Ϫ/Ϫ mice. ␣ 2 -Receptors were originally described as the adrenoceptors acting in a presynaptic feedback loop to inhibit neurotransmitter release from adrenergic nerves (for review, see Starke 28 ). Indeed, presynaptic feedback inhibition was completely deficient in ␣ 2ABC Ϫ/Ϫ mice on the basis of the following results: (1) The endogenous sympathetic neurotransmitter norepinephrine could not inhibit the electrically evoked release of were increased in ␣ 2ABC Ϫ/Ϫ mice. (4) Chronic elevation of sympathetic tone led to the typical signs of cardiac damage, left ventricular hypertrophy and fibrosis. In addition, typical pharmacological effects of ␣ 2 -agonists, including hypotension, sedation, and analgesia, were completely absent in ␣ 2ABC Ϫ/Ϫ -deficient mice. Taken together, these experiments demonstrate that ␣ 2ABC Ϫ/Ϫ mice do not express any functional ␣ 2 -adrenoceptors.
Most surprisingly, clonidine elicited significant bradycardic effects in vivo and in isolated atria of ␣ 2ABC Ϫ/Ϫ mice. Previously, some authors have reported that clonidine inhibited spontaneous beating frequency in isolated atria or Langendorff heart preparations. 29, 30 The bradycardic effect could be traced back to the sinus node, because clonidine also inhibited spontaneous beating frequency of isolated right atria from ␣ 2ABC Ϫ/Ϫ mice. This effect was not mediated via G i/ocoupled receptors, because pretreatment with pertussis toxin to inactivate this signaling pathway did not affect the bradycardia observed in isolated atria. In contrast, clonidineinduced bradycardia was eliminated in the presence of Cs ϩ , which blocks I f current. Electrophysiological measurements in SAN cells confirmed that clonidine inhibits I f in the low micromolar range (IC 50 values Ϸ3 mol/L). Importantly, IC 50 values in SAN cells were identical for both genotypes. Heterologously expressed HCN4 and HCN2 channels revealed an Ϸ3-fold lower sensitivity to clonidine (IC 50 values Ϸ9 mol/L). The slight difference from wild-type channels may be explained by the fact that in SAN cells, HCN channels are probably assembled with modulatory subunits and scaffolding proteins that are not present in HEK293 cell lines. 31, 32 Nevertheless, the affinities determined for clonidine are well in the range of those found for other blockers of I f , such as ZD7288, cilobradine, or ivabradine, which all block I f at low micromolar concentrations. 2, 33 As a consequence of blocking I f , clonidine reduced the steepness of diastolic depolarization and hence the frequency of pacemaker potentials. The molecular identity of the clonidine binding site is not yet known. Hill coefficients for clonidine of Ϸ1 suggest that there is only 1 binding site for this agent in the tetrameric HCN channel complex. Given that the pore blocker Cs ϩ induced a rightward shift of the clonidine binding curve, which is a hallmark of competitive binding, it is intriguing to speculate that the clonidine binding region is localized within or very close to the channel pore.
One of the important questions is whether inhibition of HCN channels contributes to the pharmacological actions of clonidine in vivo. The present experiments with ECG telemetry in conscious, freely moving ␣ 2ABC Ϫ/Ϫ mice demonstrated that clonidine doses starting at 10 g/kg elicited a significant bradycardic effect (Figure 4b ). Most importantly, at all doses tested in the present study, the bradycardic effect of clonidine in ␣ 2ABC Ϫ/Ϫ mice was 26% to 43% of its effect in wild-type mice. This indicates that in vivo inhibition of cardiac HCN channels by clonidine occurs in the same dose range as ␣ 2 -receptor activation (ie, 10 to 300 g/kg) (Figure 4b ). These clonidine doses are at the lower end of the spectrum of doses (30 g/kg to 50 mg/kg 34 -36 ) that have previously been used to investigate ␣ 2 -adrenoceptor-mediated functions in mice. The present findings in mice are consistent with a recent report demonstrating that clonidine elicited significant bradycardia but no hypotension in mice with a targeted mutation (D79N) in the ␣ 2A -adrenoceptor gene. 34 -36 Furthermore, the clonidine doses applied in the present study are significantly lower than doses determined for specific I f channel inhibitors. For example, the ED 50 value of ivabradine, the only I f channel inhibitor that has been introduced into therapy so far, is Ϸ5 mg/kg in mice. 33 However, it remains to be determined whether the observed bradycardia also contributes to the therapeutic effects of clonidine in humans. Clonidine doses used for antihypertensive therapy in humans are typically in the range of 150 to 900 g/d, but doses up to 3600 g/d have also been used in patients with essential hypertension. 37 Interestingly, in tetraplegic patients with complete cervical spinal cord transsection and preganglionic sympathetic denervation, clonidine significantly lowered heart rate without affecting blood pressure. 38 Inhibition of cardiac HCN channels by clonidine in humans may be of particular relevance during high-dose application of the drug, including rapid intravenous injection during hypertensive crisis or opioid detoxification. 39 The present data do not lend support to the "imidazoline hypothesis" of the action of clonidine. We have not been able to obtain any results that are consistent with the HCN channel being an "imidazoline receptor." According to the imidazoline hypothesis, I 1 receptor agonists should lower blood pressure, but they are not reported to be specific bradycardic agents. 6, 40 The present data are in line with previous reports that indicated that certain derivatives of clonidine, including N-allyl-clonidine (alinidine), act as specific bradycardic agents. 41 In conclusion, clonidine can directly inhibit cardiac HCN pacemaker channels and elicit a strong bradycardic effect. This finding may be of great relevance for other neuronal effects of clonidine and other ligands with imidazoline structure, because HCN channels are ubiquitously expressed in the nervous system. Thus, clonidine-like drugs with imidazoline structure may become novel lead structures in the search for future HCN channel inhibitors.
